Regenxbio Inc is a biotechnology company focused on advancing the field of gene therapy for the treatment of rare and debilitating diseases. The company specializes in developing innovative therapies that utilize its proprietary AAV (adeno-associated virus) gene delivery technology, which aims to correct genetic defects and restore normal function at the cellular level. Regenxbio is committed to addressing unmet medical needs through its robust pipeline of product candidates, targeting various conditions, including inherited retinal diseases and neurodegenerative disorders. By harnessing the power of gene therapy, Regenxbio seeks to transform treatment options and improve the quality of life for patients. Read More
Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired REGENXBIO, Inc. (NASDAQ: RGNX) securities between February 9, 2022 and January 27, 2026. REGENXBIO is a clinical-stage biotechnology company providing gene therapies that deliver functional genes to cells with genetic defects in the United States.
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”). REGENXBIO is a clinical-stage biotechnology company.
The multi-billion dollar wet Age-Related Macular Degeneration (wet AMD) market is standing on the precipice of a transformative shift. Today, February 16, 2026, Ocular Therapeutix (NASDAQ: OCUL) is in its final "quiet period" before releasing the highly anticipated topline results for its SOL-1 Phase 3 trial. The data, expected to
Big pharma and biotech take the earnings stage with reports from Eli Lilly and Novo Nordisk leading the lineup. Will they help the industry once again outperform AI champ Nvidia?
REGENXBIO said on Monday that the U.S. Food and Drug Administration (FDA) denied approval for its gene therapy in treating Hunter syndrome, outlining several reasons for the denial.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of REGENXBIO Inc. (“Regenxbio” or “the Company”) (NASDAQ: RGNX) for violations of the securities laws.
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of REGENXBIO Inc. (“Regenxbio” or the “Company”) (NASDAQ: RGNX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, NY - January 28, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against REGENXBIO Inc. (“REGENXBIO” or the “Company”) (NASDAQ: RGNX).
REGENXBIO stated that the FDA has placed a clinical hold on the company’s experimental gene therapy program for the treatment of rare childhood diseases.
December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an eight-year high. The dramatic ascent follows the announcement of overwhelmingly positive top-line results from its pivotal Phase 3 HOPE-3 study for
REGENXBIO beats Q3 2025 earnings estimates with strong revenue and a narrower loss. Key gene therapy RGX-202 advances, with topline data expected in early 2026.
The global economy is sailing into Q3 2025 with a blend of cautious optimism and persistent challenges. While a new tariff regime and elevated geopolitical tensions introduce elements of uncertainty, the underlying currents suggest continued, albeit slower, economic expansion, particularly within the United States. Investors are keenly watching the interplay
